| Formulary Chapter 9: Nutrition and blood - Full Chapter
|
 |
Preparations may contain peanut and soya oil (suitable for vegetarians). Check allergy status prior to prescribing. |
|
Colecalciferol
|
Formulary
|
Capsules: 800 units, 20,000 units
Tablets: 800units, 1000units, 25,000 units
Liquid: Secondary care: contact pharmacy for advice regarding available brands. Primary care: use most clinically and cost effective option
Note, for bariatric indications
|
Colecalciferol and Calcium Carbonate
|
Formulary
|
Please note, the following preparations are listed generically. Please be aware that the branded products issued by primary and secondary care, and patients may be changed onto an equivalent preparation depending on which products are most cost-effective.
Tablets: 1.5g Calcium Carbonate (600mg Calcium) and 400 units (10mcg) Colecalciferol
Chewable tablets: 1.5g Calcium Carbonate (600mg Calcium) and 400 units (10mcg) Colecalciferol
Eff Tablets: 1.5g Calcium Carbonate (600mg Calcium) and 400 units (10mcg)
Caplets: 750mg calcium carbonate (300mg Calcium) an 200units (5mcg) – used by secondary care, review use in primary care as more cost-effective options are available.
Secondary care: contact pharmacy for advice regarding available brands. Primary care: use most clinically and cost effective option
|
Dihydrotachysterol (AT 10®)
|
Non Formulary
|
|
Key |
|
|
|
|
Cytotoxic Drug
|
|
|
Controlled Drug
|
|
High Cost Medicine
|
|
Cancer Drugs Fund
|
|
NHS England |
|
Homecare |
|
CCG |
|
Traffic Light Status Information
| Status |
Description |
|
Drugs for hospital use or use by a specialist within specialist centre only. Initiation and monitoring of treatment should remain under the total responsibility of the appropriate hospital clinician or specialist.
These drugs should only be prescribed under the direct supervision of that clinician or specialist and are not suitable for shared care arrangements. The drug should be supplied via the hospital or specialist centre for the duration of treatment.
|
|
These are specialist drugs which must be initiated by secondary care specialist prescribers, but with the potential to transfer prescribing to primary care within written and agreed shared care protocols and according to the agreed process for transfer of care.
For these drugs, in order to ensure patient safety, some aspects of care must remain with the specialist due to their complexity e.g. monitoring of disease or drug response. Other more routine aspects can be transferred to the GP e.g. monitoring of adverse effects and supply of the medicine. The specific responsibilities of the specialist and GP are defined in the shared care agreement for each drug.
Shared care agreements are still under development for some amber drugs. Until these are available, it would be expected that any shared care request from secondary care to a GP would be accompanied by written information which defines prescribing and monitoring responsibilities. The hospital specialist should also provide the GP with enough information and support to allow the safe transfer and ongoing management of prescribing into primary care.
|
|
Drugs which should usually be initiated in secondary care, or by a specialist clinician, but can be safely maintained in primary care with very little or no monitoring required. In some cases there may be a further restriction for use outlined - these will be defined in each case. |
|
These are defined as new and established drugs, which may be prescribed, initiated, changed or maintained on FP10 by the GP and, if appropriate, discontinued without recourse to secondary care.
N.B. DRUGS NOT IDENTIFIED IN THE FORMULARY BY A RED, AMBER OR GREEN+ SYMBOL ARE CLASSIFIED AS GREEN. |
|
|
